U.S. FDA Grants Full Approval to Amgen’s IMDELLTRA®, Marking a Significant Advance for Extensive Stage Small Cell Lung Cancer
Amgen’s groundbreaking drug IMDELLTRA has secured full FDA approval for extensive stage SCLC based on compelling Phase 3 data. It reduced the risk of death by 40%, offering a major advance for relapsed patients.
